Ocular Therapeutix, Inc.
DE ˙ DB ˙ US67576A1007
7,15 € ↑0,25 (3,62%)
2026-06-04
DEL PRIS
SecurityDE:0OT / Ocular Therapeutix, Inc.
InstitutionOpaleye Management Inc.
Latest Disclosed Ownership4,342,500 shares
Ownership 2.76%
Opaleye Management Inc. ownership in 0OT / Ocular Therapeutix, Inc.

2025-02-14 - Opaleye Management Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,342,500 shares of Ocular Therapeutix, Inc. (DE:0OT). This represents 2.76 percent ownership of the company. In their previous filing dated 2024-02-14 , Opaleye Management Inc. had reported owning 6,070,000 shares, indicating a decrease of -28.46 percent.

Opaleye Management Inc. has a history of taking positions in derivatives of the underlying security (0OT) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2025-02-14 2025-02-14 13G/A 6,070,000 4,342,500 -28.46 2.76 -49.91
2024-02-14 2024-02-14 13G/A 6,075,000 6,070,000 -0.08 5.51 -30.16
2023-02-13 2023-02-13 13G/A 5,974,800 6,075,000 1.68 7.89 1.15
2022-02-01 2022-02-01 13G/A 5,974,800 7.80 -29.09
2021-02-12 2021-02-12 13G/A 11.00 0.00
2020-01-10 2020-01-10 13G/A 11.00 0.00
2019-05-03 2019-05-03 13G 11.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:0OT / Ocular Therapeutix, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F OCULAR THERAPEUTIX COM 67576A100 600,000 -995,000 -62.38 5,082 -73.75 0.6694
2026-04-13 2025-12-31 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 1,595,000 0 0.00 19,363 3.85 2.5549
2026-02-17 2025-12-31 13F OCULAR THERAPEUTIX COM 67576A100 1,595,000 0 19,363 2.5546
2025-11-14 2025-09-30 13F OCULAR THERAPEUTIX COM 67576A100 1,595,000 0 0.00 18,646 25.97 2.6361
2025-08-15 2025-06-30 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 1,595,000 0 0.00 14,802 26.60 2.9954
2025-08-14 2025-06-30 13F OCULAR THERAPEUTIX COM 67576A100 1,595,000 0 14,802 2.9667
2025-05-15 2025-03-31 13F OCULAR THERAPEUTIX COM 67576A100 1,595,000 -2,747,500 -63.27 11,691 -68.47 2.6030
2025-02-14 2024-12-31 13F OCULAR THERAPEUTIX COM 67576A100 4,342,500 -682,500 -13.58 37,085 -15.17 6.4899
2024-11-14 2024-09-30 13F OCULAR THERAPEUTIX COM 67576A100 5,025,000 -282,500 -5.32 43,718 20.42 7.2916
2024-08-14 2024-06-30 13F OCULAR THERAPEUTIX COM 67576A100 5,307,500 -1,345,638 -20.23 36,303 -40.04 8.2949
2024-05-29 2024-03-31 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 6,653,138 583,138 9.61 60,544 123.64 13.1944
2024-05-15 2024-03-31 13F OCULAR THERAPEUTIX COM 67576A100 6,653,138 583,138 60,544 13.8565
2024-02-14 2023-12-31 13F OCULAR THERAPEUTIX COM 67576A100 6,070,000 -398,000 -6.15 27,072 33.30 7.1988
2023-11-15 2023-09-30 13F OCULAR THERAPEUTIX COM 67576A100 6,468,000 688,000 11.90 20,310 -31.90 6.6073
2023-08-14 2023-06-30 13F OCULAR THERAPEUTIX COM 67576A100 5,780,000 -325,900 -5.34 29,825 -7.32 7.1340
2023-05-15 2023-03-31 13F OCULAR THERAPEUTIX COM 67576A100 6,105,900 30,900 0.51 32,178 88.51 9.6377
2023-02-10 2022-12-31 13F OCULAR THERAPEUTIX COM 67576A100 6,075,000 -390,000 -6.03 17,071 -36.38 5.9362
2022-11-14 2022-09-30 13F OCULAR THERAPEUTIX COM 67576A100 6,465,000 490,200 8.20 26,830 11.70 11.0807
2022-08-15 2022-06-30 13F OCULAR THERAPEUTIX COM 67576A100 5,974,800 0 0.00 24,019 -18.79 10.8265
2022-05-16 2022-03-31 13F OCULAR THERAPEUTIX COM 67576A100 5,974,800 0 0.00 29,575 -28.98 9.1848
2022-02-14 2021-12-31 13F OCULAR THERAPEUTIX COM 67576A100 5,974,800 -505,200 -7.80 41,644 -35.73 8.8325
2021-11-16 2021-09-30 13F OCULAR THERAPEUTIX COM 67576A100 6,480,000 0 0.00 64,800 -29.48 12.1033
2021-08-16 2021-06-30 13F OCULAR THERAPEUTIX COM 67576A100 6,480,000 0 0.00 91,886 -13.59 15.2619
2021-05-18 2021-03-31 13F OCULAR THERAPEUTIX COM 67576A100 6,480,000 -30,000 -0.46 106,337 -21.09 15.6193
2021-02-12 2020-12-31 13F OCULAR THERAPEUTIX COM 67576A100 6,510,000 525,800 8.79 134,758 195.91 17.6023
2020-11-16 2020-09-30 13F OCULAR THERAPEUTIX COM 67576A100 5,984,200 0 0.00 45,540 -8.64 8.9064
2020-08-14 2020-06-30 13F OCULAR THERAPEUTIX COM 67576A100 5,984,200 861,700 16.82 49,848 96.59 10.0673
2020-05-15 2020-03-31 13F OCULAR THERAPEUTIX COM 67576A100 5,122,500 15,000 0.29 25,356 25.68 6.7193
2020-02-14 2019-12-31 13F OCULAR THERAPEUTIX COM 67576A100 5,107,500 2,332,500 84.05 20,175 139.15 3.9586
2019-11-14 2019-09-30 13F OCULAR THERAPEUTIX COM 67576A100 2,775,000 -175,000 -5.93 8,436 -35.01 3.0505
2019-08-14 2019-06-30 13F OCULAR THERAPEUTIX COM 67576A100 2,950,000 1,050,000 55.26 12,980 72.08 3.9562
2019-05-15 2019-03-31 13F OCULAR THERAPEUTIX COM 67576A100 1,900,000 1,900,000 7,543 2.0887
2019-02-14 2018-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -800,000 -100.00 0 -100.00
2018-11-14 2018-09-30 13F OCULAR THERAPEUTIX COM 67576A100 800,000 -311,000 -27.99 5,504 -26.60 1.4003
2018-08-14 2018-06-30 13F OCULAR THERAPEUTIX COM 67576A100 1,111,000 0 0.00 7,499 3.69 1.9409
2018-05-14 2018-03-31 13F OCULAR THERAPEUTIX COM 67576A900 1,111,000 1,111,000 7,232 2.0678
2017-08-14 2017-06-30 13F OCULAR THERAPEUTIX COM 67576A100 0 -550,000 -100.00 0 -100.00
2017-05-15 2017-03-31 13F OCULAR THERAPEUTIX COM 67576A100 550,000 456,400 487.61 5,104 551.85 2.5402
2017-02-21 2016-12-31 13F OCULAR THERAPEUTIX COM 67576A100 93,600 -166,400 -64.00 783 -39.16 0.4614
2016-08-12 2016-06-30 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 260,000 260,000 1,287 0.8597
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-08-14 2020-06-30 13F OCULAR THERAPEUTIX CALL Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-15 2020-03-31 13F OCULAR THERAPEUTIX CALL Call 1,000 53 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.